Please login or register first to view this content.
Immune Disorders Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
NEWS & FEATURES
August 2022 Recap: Drug Pipeline Update
Imbruvica Approved for Pediatric Patients With Chronic Graft-vs-Host Disease
Deoxycytidine Kinase Inhibitor Designated Orphan Drug for Optic Neuritis
Benlysta Approval Expanded to Include Pediatric Lupus Nephritis
Risk for Guillain-Barré Syndrome Up After Ad.26.COV2.S Vaccination
Efzofitimod Granted Orphan Drug Status for Systemic Sclerosis
FDA Extends Shelf Life of Immune Globulin Products Asceniv and Bivigam
Jergens Moisturizer Recalled Due to Bacteria Risk
Certain Immune Globulin Products Withdrawn Due to Higher Rate of Hypersensitivity Reactions
Lilly Ends Baricitinib Lupus Program, Provides Update on Atopic Dermatitis sNDA
Biosimilars Could Cut Spending for Biologic Therapy in the US
Novel Immunomodulator Gets Orphan Drug Status for Sarcoidosis
Orencia Approved for Prevention of Acute Graft Versus Host Disease
Cutaquig Approved for Pediatric Patients With Primary Humoral Immunodeficiency
October 2021: 5 Notable Drug Approvals
Doctors Report That Kidney Grown in Pig Worked in a Human
Potential Safety Concern for Guillain-Barré Syndrome ID’d for Ad26.COV2.S
Cudetaxestat Gets Orphan Drug Status for Systemic Sclerosis
